Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS

Trial Profile

AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Molgramostim (Primary)
  • Indications Pulmonary alveolar proteinosis
  • Focus Adverse reactions; Registrational
  • Acronyms IMPALA-EX; IMPALA-X
  • Sponsors Savara Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2019 According to a Savara Pharmaceuticals media release, 32 out of 35 eligible patients have enrolled in the extension study, with no whole lung lavages reported and no drop-outs to-date.
    • 13 Mar 2019 According to a Savara Pharmaceuticals media release, at the end of Q4 2018, 20 out of 21 eligible patients had enrolled in the extension study.
    • 06 Feb 2019 According to a Savara Pharmaceuticals media release, enrollment in this study continues to be active.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top